Observational study to find out efficacy and safety of Bifidobacterium longum W11 plus Fructooligosaccharide combination in patients with irritable bowel syndrome
- Conditions
- Health Condition 1: K519- Ulcerative colitis, unspecified
- Registration Number
- CTRI/2024/07/070510
- Lead Sponsor
- Abbott India Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients of either sex, aged between 18 and 60 years
OPD Patients with confirmed diagnosis of IBS with any of the three subtypes (viz IBS D/IBS C/IBS M)
Patients with no improvement in symptoms despite treatment with antispasmodics
Patients will be excluded if they have severe respiratory insufficiency organic brain damage sleep apnea syndrome severe acute or chronic
hepatic insufficiency (risk of occurrence of encephalopathy) myasthenia gravis chronic psychosis major depressive episodes
phobic or obsessional states or dementia
Patients with other pre-existing GI disorders GI surgery abnormal upper and lower GI endoscopy finding family history of colon cancer or inflammatory bowel disease symptoms that discriminate lower GI organic diseases from IBS such as blood in stool nighttime symptoms
that cause sleep disturbance unintentional weight loss or change in typical IBS symptoms such as new and/or different pain and alcohol or drug-dependency
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method